Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
2.340
-0.010 (-0.43%)
At close: Aug 7, 2025, 4:00 PM
2.370
+0.030 (1.28%)
Pre-market: Aug 8, 2025, 8:21 AM EDT
Nuvation Bio Revenue
Nuvation Bio had revenue of $4.83M in the quarter ending June 30, 2025, with 236.79% growth. This brings the company's revenue in the last twelve months to $14.36M, up 900.35% year-over-year. In the year 2024, Nuvation Bio had annual revenue of $7.87M.
Revenue (ttm)
$14.36M
Revenue Growth
+900.35%
P/S Ratio
52.60
Revenue / Employee
$65,250
Employees
220
Market Cap
796.22M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7.87M | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
NUVB News
- 1 day ago - Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 3 days ago - Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses - Business Wire
- 14 days ago - Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 - Business Wire
- 6 weeks ago - Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers - Business Wire
- 7 weeks ago - Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc. - GlobeNewsWire
- 2 months ago - US FDA approves Nuvation Bio's lung cancer therapy - Reuters
- 2 months ago - U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer - Business Wire
- 2 months ago - Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting - Business Wire